国产银屑病新药信美悦匹康奇拜单抗北京首方落地

Core Viewpoint - The launch of the first domestically produced IL-23p19 monoclonal antibody, Pikangqibai injection, marks a significant milestone in the treatment of psoriasis in China, providing patients with a more effective and convenient treatment option [1][2]. Group 1: Product Launch and Significance - Pikangqibai injection is the first IL-23p19 monoclonal antibody developed in China, breaking the reliance on imported drugs for this treatment [2]. - The first prescription for Pikangqibai was issued at Peking University People's Hospital, indicating its availability in the Beijing region [1]. - The introduction of this drug represents a technological breakthrough in the long-term management of psoriasis, offering a new quarterly dosing regimen [3]. Group 2: Patient Impact and Treatment Efficacy - Approximately 7 million people in China suffer from psoriasis, with a significant portion requiring systemic treatment due to the chronic nature of the disease [1]. - Clinical trial data from the CLEAR-1 study shows that 80.3% of patients achieved a PASI 90 response by week 16, making it the first IL-23p19 antibody to surpass this threshold in a registered phase III trial [2]. - The quarterly dosing schedule not only reduces the treatment burden for patients but also maintains long-lasting efficacy, which is crucial for managing chronic conditions like psoriasis [3].